Chittaranjan Andrade

New Capabilities

Publicly critical of the trial's effect size

A single dose of mebufotenin benzoate nasal spray reduced depression scores for at least eight weeks in a 193-patient phase 2b trial published in the Journal of the American Medical Association. The psychedelic compound, found in Sonoran Desert toad venom, cut scores on the Montgomery-Åsberg Depression Rating Scale (MADRS) by 11.1 points at day 29 with a 12-milligram dose, versus 5.8 points for a 0.3-milligram comparator.

Updated Oct 28